Tofacitinib Citrate May Stimulate Hair Regrowth in Alopecia Areata

Share this content:
Tofacitinib Citrate May Stimulate Hair Regrowth in Alopecia Areata
Tofacitinib Citrate May Stimulate Hair Regrowth in Alopecia Areata

THURSDAY, Sept. 22, 2016 (HealthDay News) -- A drug used for rheumatoid arthritis might regrow hair in alopecia areata (AA) patients, according to a study published online Sept. 22 in JCI Insight.

Brett King, M.D., an assistant professor of dermatology at the Yale School of Medicine in New Haven, Conn., and colleagues included patients with AA with >50 percent scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU). Participants were treated with 5 mg of tofacitinib citrate (Xeljanz) twice a day for three months. The team assessed regrowth of scalp hair (via severity of alopecia tool [SALT]), duration of hair growth after cessation of therapy, and disease transcriptome.

The researchers found that 32 percent of 66 patients treated with tofacitinib citrate experienced 50 percent or greater improvement in SALT score. AA cases were more responsive than AT and AU cases. Disease relapse occurred in 8.5 weeks following drug cessation. Side effects were mild, limited to grade I and II infections.

"At the dose and duration studied, tofacitinib is a safe and effective treatment for severe AA, though it does not result in a durable response," the authors write. "Transcriptome changes reveal unexpected molecular complexity within the disease."

One author disclosed financial ties to pharmaceutical companies, including Pfizer, which manufactures tofacitinib citrate.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

900 Steps Tied to Functional Decline in Hospitalized Seniors

<900 Steps Tied to Functional Decline in Hospitalized ...

Walking <900 steps/day linked to hospitalization-associated functional decline

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

Does not prevent venous thromboembolism after knee arthroplasty, casting of lower leg

ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

ASH: Lower Rate of Sickle Cell Pain Crises ...

Lower rate of crises per year; longer median time to first, second crises with high-dose therapy

is free, fast, and customized just for you!

Already a member?

Sign In Now »